1,600
Participants
Start Date
February 23, 2017
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
JYNNEOS (Liquid Formulation)
Two doses of attenuated live virus smallpox vaccine (JYNNEOS liquid formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 10\^8 Tissue Culture Infectious Dose 50 \[TCID50\] per 0.5 mL). A subset of participants will receive a booster dose.
JYNNEOS (Lyophilized Formulation)
Two doses of attenuated live virus smallpox vaccine (JYNNEOS lyophilized formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 10\^8 Tissue Culture Infectious Dose 50 \[TCID50\] per 0.5 mL). A subset of participants will receive a booster dose.
Tshuapa site, Boende
Collaborators (1)
Ministry of Public Health, Democratic Republic of the Congo
OTHER_GOV
Kinshasa School of Public Health
OTHER
Bavarian Nordic
INDUSTRY
Centers for Disease Control and Prevention
FED